Stock Region Penny Picks
Stock Region Penny Picks Watchlist Newsletter - Monday, April 28, 2025.
Stock Region Penny Picks Watchlist Newsletter - Monday, April 28, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is intended for informational purposes only and should not be considered financial advice. Always conduct your own research or consult with a professional before making investment decisions.
$SNTI - Senti Bio
Update: Positive preliminary clinical results for SENTI-202 show potential in treating relapsed/refractory Acute Myeloid Leukemia (AML). This first-in-class CAR NK cell therapy could represent a major advancement in the biotech space.
$GNPX - Genprex
Update: Genprex has secured an exclusive technology license agreement with NYU Langone Health for a mesothelioma treatment. This partnership could drive innovation in combating this rare but aggressive cancer.
$GLMD - Galmed Pharmaceuticals
Update: Galmed has signed a term sheet to develop a novel sublingual formulation of semaglutide. If successfully developed, this could offer a new delivery method for the widely used treatment and potentially expand market reach.
$THAR - Tharimmune
Update: Tharimmune has made progress on TH104 for preventing high-potency opioid exposure, including weaponized fentanyl, following promising FDA feedback. The development aligns with the ongoing fight against opioid misuse and potential biothreats.
$LTRY - Lottery.com
Update: Lottery.com advances its $250M growth strategy with a focus on strategic acquisitions and shareholder engagement.
$OMEX - Odyssey Marine Exploration
Update: Odyssey confirms sufficient operational funding and highlights support from a new executive order. With these updates, the company appears positioned for stability and future growth.
$KSCP - Knightscope
Update: Ascendiant Capital maintains a "Buy" rating on Knightscope but adjusts the price target to $30. Investors should keep an eye on the evolving trajectory for this robotic security company.
$CTMX - CytomX Therapeutics
Update: CytomX, in partnership with Moderna, presented preclinical data on its mRNA-encoded Masked IL-12 Molecule.
$CASK - Heritage Distilling Co.
Update: Heritage Distilling has regained Nasdaq compliance after rectifying a prior notice of non-compliance.
$BYON - Beyond, Inc.
Update: Beyond, Inc. reports significant financial improvements and signals readiness for its revenue growth phase.
$TVGN - Tevogen
Update: Tevogen reaffirmed its oncology revenue forecast of $1 billion in its launch year, projecting cumulative 5-year revenue between $10B and $14B. These optimistic forecasts underline the company’s growth potential in oncology therapies.
Disclaimer: Stock performance can be unpredictable. This newsletter does not serve as a recommendation to buy or sell any securities. Always analyze market conditions and your personal financial situation before making investment decisions.
We are working endlessly to provide free insights on the stock market every day, and greatly appreciate those who are paid members supporting the development of the Stock Region mobile application. Stock Region offers daily stock and option signals, watchlists, earnings reports, technical and fundamental analysis reports, virtual meetings, learning opportunities, analyst upgrades and downgrades, catalyst reports, in-person events, and access to our private network of investors for paid members as an addition to being an early investor in Stock Region. We recommend all readers to urgently activate their membership before reaching full member capacity (500) to be eligible for the upcoming revenue distribution program. Memberships now available at https://stockregion.net